Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing ...
Why Parabilis Medicines Stock Is On Investors’ Radar Parabilis Medicines (PBLS) has recently drawn fresh attention after a sharp single day move, with the stock closing at $27.26 and down around 10% ...
Hosted on MSN
How to play PBLS stock after the Parabilis IPO
Parabilis Medicines (PBLS) had a thunderous debut on Nasdaq this week — opening at a little over $33, up an exciting 67% versus the $20 initial public offering (IPO) price. PBLS raised some $670 ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Parabilis Medicines, Inc. (PBLS) priced its initial public offering of 33.5 million shares at $20.00 per share, the company... Investing.com -- Parabilis Medicines Inc.’s initial public offering is ...
Transaction value based on SEC Form 4 weighted average purchase price ($27.06); post-transaction value based on June 18, 2026 market close ($25.85). Develops cell-penetrating miniproteins (CPMPs) ...
PBLS Company Profile Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results